A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Stopped The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been approved).The sponsor terminated the trial.

Conditions

• Hepatocellular Carcinoma (HCC)

Interventions

• DRUG: HLX10
• DRUG: HLX04
• DRUG: Sorafenib

Sponsor

Shanghai Henlius Biotech